Table 1.
Summary of TAM-targeting Therapies in Clinical Trials.
| Treatment Strategy | Agent Name | Mechanism | Phase | Clinical Trial Number/Reference * |
|---|---|---|---|---|
| Limiting monocyte recruitment | PF-04136309 | CCR2 antagonist | 1b | NCT01413022 [89] |
| CCX872 | CCR2 antagonist | 1b | NCT02345408 [90] | |
| Carlumab | CCL2 antibody | Ib | NCT01204996 [91] | |
| I | NCT00537368 [92] | |||
| II | NCT00992186 [93] | |||
| LY2510924 | CXCR4 antibody | I | NCT02737072 [94] | |
| Motixafortide | CXCR4 antagonist | IIb | NCT02907099 [95] | |
| Depleting TAMs | PLX3397 | CSF-1R antibody | III | NCT02371369 [96] |
| Ib | NCT01525602 [97] | |||
| RG7155 | CSF-1R antibody | I | NCT01494688 [98] | |
| AMG 820 | CSF-1R antibody | I | NCT01444404 [99] | |
| IMC-CS4 | CSF-1R antibody | I | NCT01346358 [100] | |
| MCS110 | CSF-1 antibody | Ib/II | NCT02807844 [101] | |
| Reprogramming TAMs | Imiquimod | TLR7 agonist | II | NCT00899574 [102] |
| Motolimod | TLR8 agonist | II | NCT01836029 [103] | |
| APX005M | CD40 agonist | I/II | NCT03214250 [104] | |
| RO7009789 | CD40 agonist | I | NCT02665416 | |
| SEA-CD40 | CD40 agonist | I | NCT02376699 | |
| CP-870893 | CD40 agonist | I | NCT01103635 | |
| IPI-549 | PI3Kγ inhibitor | Ib | NCT02637531 | |
| II | NCT03961698 | |||
| Targeting inhibitory molecules on TAMs | Hu5F9-G4 | CD47 antibody | I | NCT02216409 [105] |
| I/II | NCT02953509 [106] | |||
| I | NCT03558139 | |||
| I/II | NCT02953782 | |||
| CC90002 | CD47 antibody | I | NCT02367196 | |
| TTI-621 | SIRP antibody | I | NCT02663518 | |
| I/II | NCT04996004 | |||
| CC-95251 | SIRP antibody | I | NCT03783403 |
* Reference is included when trial has published results.